

🐛 400-901-9800

🔀 sales@bioss.com.cn


🔀 support@bioss.com.cn

Product Details

Product name:	Anti-BCMA & CD3 (Elranatamab Biosimilar)	SKU:	BIO0967SM
Target Name:	BCMA & CD3	Size:	100ug/ 1mg/ 5mg
Target Uniprot:	Q02223 & P07766	Concentration:	Lyophilized
Clone#:	Elranatamab (Bispecific)	Isotype:	IgG-like
Reactivity:	Human	Calculated M.W.:	145.44 kDa
Application:	ELISA, Bioactivity: FACS, Functional assay, Research in vivo	Endotoxin:	<0.001 EU/ug
Formulation:	100 mM Pro-Ac 20mM Arg pH 5.0	Conjugation:	None
Storage:	-20°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions; Avoid repeated freeze-thaw cycles.	Expression System:	СНО
Reconstitution:	Dissolve with sterile ddH ₂ O	Purification:	Protein A


Data

Purity: SDS-PAGE




Anti-BCMA & CD3 Reference Antibody (Elranatamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

ELISA




 $Elranatamab-Bcmm \ bound \ to \ BCMA \ protein, \ and \ then \ rebounded \ to \ secondary \ antibodies \ (Anti-human-IgG-Fc-HRP) \ , \ and \ read \ OD450. \ Ashown \ in \ fig, \ Elranatamab-Bcmm \ bound \ to \ huBCMA-ECD-His \ , \ and \ the \ EC50 \ was \ 0.055 \ nM.$

Purity: SEC-HPLC



The purity of Anti-BCMA & CD3 Reference Antibody (Elranatamab) is 99.34% , determined by SEC-HPLC.

Bioactivity: FACS



Elranatamab-Bcmm bound to huBCMA-HEK293 cells, and then rebounded fluorescent secondary antibodies (Anti-human IgG, Fc γ PE), and test by flow cytometry. As shown in fig, Elranatamab-Bcmm bound to huBCMA-HEK293 cells, and the EC50 was 1.263 nM.


Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.



↓ 400-901-9800
sales@bioss.com.cn


🔀 support@bioss.com.cn

Bioactivity: FACS



Elranatamab-Bcmm bound to huCD3e-jurkat cells, and then reboundedo fluorescent secondary antibodies (Anti-human IgG, Fc γ PE), and test by flow cytometry. As shown in fig, Elranatamab-Bcmm bound to huCD3e-jurkat cells, and the EC50 was 64.990 nM.

Function: Luciferase



Co-incubation of Elranatamab-Bcmm with Jurkat cells, then with thaddition of huBCMA-HEK293 cells for 6 hours. Bright-Lite was used to detect the fluorescent signal.As shown in fig, Elranatamab-Bcmmwas able to activate the NF-AT signaling pathway, and the EC50 was 0.081 nM.